INDV Indivior Pharmaceuticals, Inc.

8-K Current Report
Filed: February 26, 2026
Health Care
Pharmaceutical Preparations

Indivior Pharmaceuticals, Inc. (INDV) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

  • Item 2.02: Results of Operations and Financial Condition
  • Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

  • Full-year 2025 earnings release issued Feb 26, 2026 — financial details in Exhibit 99.1
  • Covers fiscal year ended Dec 31, 2025 — annual results, not a quarterly update

Item 7.01 · Regulation FD Disclosure

  • Indivior posted investor presentation materials (Exhibit 99.2) and updated corporate presentation (Exhibit 99.3) to its website on Feb 26, 2026
  • Reg FD disclosure ensures simultaneous public access — content likely includes strategy, pipeline, or financial guidance relevant to institutional investors
+1 more insights

Other Indivior Pharmaceuticals, Inc. 8-K Filings

Get deeper insights on Indivior Pharmaceuticals, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.